Janice Wahl Selected Research

Fibrosis (Cirrhosis)

1/2018	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
11/2017	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
11/2017	Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
10/2017	Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection.
1/2017	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
1/2017	Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
12/2016	Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
7/2015	Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
3/2015	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
3/2015	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janice Wahl Research Topics

Disease

30	Infections 05/2018 - 07/2013
12	Chronic Hepatitis C 05/2018 - 07/2013
11	Fibrosis (Cirrhosis) 01/2018 - 08/2014
4	Coinfection 05/2018 - 03/2015
3	Hepatitis C 10/2017 - 01/2016
2	Pneumonia (Pneumonitis) 01/2018 - 01/2017
2	Vomiting 12/2017 - 07/2013
2	Chronic Renal Insufficiency 01/2017 - 10/2015
2	Anemia 02/2016 - 11/2013
1	Opiate Overdose 01/2018
1	Cellulitis 01/2018
1	Chest Pain (Chest Pains) 01/2018
1	Insulin Resistance 01/2018
1	Tachycardia (Tachyarrhythmias) 12/2017
1	Pruritus (Itching) 01/2017
1	Hemoglobinopathies 01/2017
1	Hemorrhage 01/2017
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2017
1	Virus Diseases (Viral Diseases) 01/2017
1	Hepatocellular Carcinoma (Hepatoma) 03/2015
1	Liver Diseases (Liver Disease) 03/2015
1	Disease Progression 01/2015
1	Neutropenia 07/2013
1	Fever (Fevers) 07/2013
1	Dysgeusia (Parageusia) 07/2013
1	Hepatitis 07/2013
1	Onychomycosis (Tinea Unguium) 09/2011

Drug/Important Bio-Agent (IBA)

25	grazoprevirIBA 05/2018 - 08/2014
21	elbasvirIBA 05/2018 - 03/2015
17	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 11/2013
8	Antiviral Agents (Antivirals)IBA 01/2018 - 07/2013
8	InterferonsIBA 11/2017 - 03/2015
7	RNA (Ribonucleic Acid)IBA 01/2018 - 07/2013
7	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 02/2016 - 07/2013
6	Protease Inhibitors (Protease Inhibitor)IBA 01/2016 - 07/2013
3	SofosbuvirIBA 01/2018 - 12/2016
3	ruzasvirIBA 12/2017 - 11/2017
3	uprifosbuvirIBA 12/2017 - 11/2017
3	Proteins (Proteins, Gene)FDA Link 10/2017 - 07/2013
2	Erythropoietin FDA Link 02/2016 - 11/2013
1	SaltsIBA 05/2018
1	CreatinineIBA 01/2018
1	Proton Pump InhibitorsIBA 10/2017
1	Hemoglobins (Hemoglobin)IBA 01/2017
1	Lipase (Acid Lipase)FDA Link 01/2017
1	TabletsIBA 01/2017
1	Opioid Analgesics (Opioids)IBA 11/2016
1	SimeprevirIBA 09/2015
1	telaprevirIBA 09/2015
1	Peptide Hydrolases (Proteases)FDA Link 07/2013
1	posaconazole FDA Link 09/2011

Therapy/Procedure

11	Therapeutics 12/2017 - 11/2013
2	Aftercare (After-Treatment) 01/2018 - 01/2015
2	Duration of Therapy 01/2017 - 03/2015
2	Drug Tapering 02/2016 - 11/2013
1	Retreatment 01/2017